1. Home
  2. CMND vs KALA Comparison

CMND vs KALA Comparison

Compare CMND & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clearmind Medicine Inc.

CMND

Clearmind Medicine Inc.

N/A

Current Price

$0.91

Market Cap

2.2M

Sector

Health Care

ML Signal

N/A

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

N/A

Current Price

$0.29

Market Cap

319.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CMND
KALA
Founded
2017
2009
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
319.6M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
CMND
KALA
Price
$0.91
$0.29
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$31.50
AVG Volume (30 Days)
64.2K
4.8M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
41.50
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$0.23
52 Week High
$3.25
$20.58

Technical Indicators

Market Signals
Indicator
CMND
KALA
Relative Strength Index (RSI) 29.70 36.82
Support Level $0.80 N/A
Resistance Level $1.07 $0.72
Average True Range (ATR) 0.09 0.05
MACD 0.01 0.00
Stochastic Oscillator 10.59 30.92

Price Performance

Historical Comparison
CMND
KALA

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: